Studies have shown that IL-23 levels are significantly elevated in the serum and synovial fluid of RA patients, with the levels correlating closely with disease activity and bone erosion, supporting the potential of IL-23 as a therapeutic target for RA. In terms of efficacy, guselkumab has demonstrated strong anti-inflammatory effects in other immune-mediated diseases, such as psoriasis and psoriatic arthritis. This evidence concerns the gene IL37 and psoriasis.